Literature DB >> 6113969

Studies on the post-ictal rise in seizure threshold.

D J Nutt, P J Cowen, A R Green.   

Abstract

Seizure thresholds were determined by timed infusion of a convulsant drug. Following an electroconvulsive shock (ECS) rats exhibited a raised seizure threshold to infusion of the GABA antagonist drugs, pentylenetetrazol, bicuculline and isopropyl-bicyclophosphate, but not to the glycine antagonist strychnine or the 5-HT agonist, quipazine. The increase in threshold was seen following a bicuculline-induced seizure and 30 min following the last of a course of ECS given once daily for 10 days. The rise in seizure threshold still occurred when animals were pretreated with alpha-methyl-p-tyrosine (200 mg . kg-1), p-chlorophenylalanine (200 mg . kg-2), naloxone (1 mg . kg-1) or indomethacin (20 mg . kg-1). Diazepam (2 mg . kg-1), flurazepam (10 mg . kg-1) and sodium valproate (400 mg . kg-1) elevated basal seizure threshold and a further rise followed the ECS. Phenytoin (40 mg . kg-1) and carbamazepine (40 mg . kg-1) had no effect on basal seizure threshold or the ECS-induce rise. (¿Propranolol (20 mg . kg-1) did not affect basal seizure threshold but prevented the ECS-induced increase. The rise in seizure threshold following a convulsion may be an important adaptive mechanism which could be related to the reported increase in specific benzodiazepine binding following a seizure.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6113969     DOI: 10.1016/0014-2999(81)90031-5

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  12 in total

1.  Interactions of the imidazodiazepine Ro 15-4513 with chemical convulsants.

Authors:  R G Lister; D J Nutt
Journal:  Br J Pharmacol       Date:  1988-01       Impact factor: 8.739

2.  Using Ro 15-1788 to investigate the benzodiazepine receptor in vivo: studies on the anticonvulsant and sedative effect of melatonin and the convulsant effect of the benzodiazepine Ro 05-3663.

Authors:  A R Green; D J Nutt; P J Cowen
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

3.  Some anticonvulsant drugs alter monoamine-mediated behaviour in mice in ways similar to electroconvulsive shock; implications for antidepressant therapy.

Authors:  A R Green; P Johnson; J A Mountford; V L Nimgaonkar
Journal:  Br J Pharmacol       Date:  1985-02       Impact factor: 8.739

4.  Action of chlormethiazole in a model of ethanol withdrawal.

Authors:  A R Green; E M Davies; H J Little; M A Whittington; A J Cross
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

5.  Seizure threshold to lidocaine is decreased following repeated ECS (electroconvulsive shock).

Authors:  J Kragh; J Seidelin; T G Bolwig
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

6.  On the convulsant action of Ro 5-4864 and the existence of a micromolar benzodiazepine binding site in rat brain.

Authors:  S E File; A R Green; D J Nutt; N D Vincent
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

7.  Acetylcholinesterase activity rises in rat cerebrospinal fluid post-ictally; effect of a substantia nigra lesion on this rise and on seizure threshold.

Authors:  M E Appleyard; A R Green; S A Greenfield
Journal:  Br J Pharmacol       Date:  1987-05       Impact factor: 8.739

8.  Regional rat brain benzodiazepine receptor number and gamma-aminobutyric acid concentration following a convulsion.

Authors:  J M Bowdler; A R Green
Journal:  Br J Pharmacol       Date:  1982-06       Impact factor: 8.739

9.  The effects of single and repeated electroconvulsive shock administration on the release of 5-hydroxytryptamine and noradrenaline from cortical slices of rat brain.

Authors:  A R Green; D J Heal; N D Vincent
Journal:  Br J Pharmacol       Date:  1987-09       Impact factor: 8.739

10.  Inhibition of the rate of GABA synthesis in regions of rat brain following a convulsion.

Authors:  A R Green; A Metz; M C Minchin; N D Vincent
Journal:  Br J Pharmacol       Date:  1987-09       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.